CN101611016B - 他拉罗唑代谢物 - Google Patents

他拉罗唑代谢物 Download PDF

Info

Publication number
CN101611016B
CN101611016B CN2007800387031A CN200780038703A CN101611016B CN 101611016 B CN101611016 B CN 101611016B CN 2007800387031 A CN2007800387031 A CN 2007800387031A CN 200780038703 A CN200780038703 A CN 200780038703A CN 101611016 B CN101611016 B CN 101611016B
Authority
CN
China
Prior art keywords
talarazole
hours
metabolites
dose
feces
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2007800387031A
Other languages
English (en)
Chinese (zh)
Other versions
CN101611016A (zh
Inventor
德布拉·巴雷特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stiefel Research Australia Pty Ltd
Original Assignee
Stiefel Research Australia Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stiefel Research Australia Pty Ltd filed Critical Stiefel Research Australia Pty Ltd
Publication of CN101611016A publication Critical patent/CN101611016A/zh
Application granted granted Critical
Publication of CN101611016B publication Critical patent/CN101611016B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN2007800387031A 2006-10-17 2007-10-17 他拉罗唑代谢物 Expired - Fee Related CN101611016B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85198906P 2006-10-17 2006-10-17
US60/851,989 2006-10-17
PCT/US2007/081685 WO2008049027A1 (en) 2006-10-17 2007-10-17 Talarazole metabolites

Publications (2)

Publication Number Publication Date
CN101611016A CN101611016A (zh) 2009-12-23
CN101611016B true CN101611016B (zh) 2012-01-25

Family

ID=39314359

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007800387031A Expired - Fee Related CN101611016B (zh) 2006-10-17 2007-10-17 他拉罗唑代谢物

Country Status (10)

Country Link
US (2) US8188124B2 (enExample)
EP (1) EP2114895A4 (enExample)
JP (1) JP5343267B2 (enExample)
KR (1) KR101419965B1 (enExample)
CN (1) CN101611016B (enExample)
AU (1) AU2007311026B2 (enExample)
BR (1) BRPI0718310A2 (enExample)
CA (1) CA2667053C (enExample)
MX (1) MX2009004096A (enExample)
WO (1) WO2008049027A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9080145B2 (en) 2007-07-01 2015-07-14 Lifescan Corporation Single pluripotent stem cell culture
CA3207103A1 (en) 2007-07-31 2009-02-05 Janssen Biotech, Inc. Differentiation of human embryonic stem cells to pancreatic endocrine
ATE523585T1 (de) 2007-11-27 2011-09-15 Lifescan Inc Differenzierung menschlicher embryonaler stammzellen
RU2551772C2 (ru) 2008-02-21 2015-05-27 Сентокор Орто Байотек Инк. Способы, поверхностно-модифицированные носители и композиции для иммобилизации, культивирования и открепления клеток
BRPI0914116A2 (pt) 2008-06-30 2019-09-17 Centocor Ortho Biotech Inc diferenciação de células-tronco pluripotentes
CN107435038B (zh) 2008-10-31 2021-07-09 詹森生物科技公司 人胚胎干细胞向胰腺内分泌谱系的分化
RU2522001C2 (ru) 2008-10-31 2014-07-10 Сентокор Орто Байотек Инк. Дифференцирование человеческих эмбриональных стволовых клеток в линию панкреатических эндокринных клеток
JP2012509085A (ja) 2008-11-20 2012-04-19 ヤンセン バイオテツク，インコーポレーテツド マイクロキャリア上での多能性幹細胞の培養
CA2744227C (en) 2008-11-20 2018-10-02 Centocor Ortho Biotech Inc. Methods and compositions for cell attachment and cultivation on planar substrates
SG177481A1 (en) 2009-07-20 2012-02-28 Janssen Biotech Inc Differentiation of human embryonic stem cells
CA2784415C (en) 2009-12-23 2019-06-18 Jean Xu Differentiation of human embryonic stem cells
SG183535A1 (en) 2010-03-01 2012-10-30 Janssen Biotech Inc Methods for purifying cells derived from pluripotent stem cells
MX351515B (es) 2010-05-12 2017-10-17 Janssen Biotech Inc Diferenciacion de celulas madre embrionarias humanas.
CN103221536B (zh) 2010-08-31 2016-08-31 詹森生物科技公司 人胚胎干细胞的分化
ES2658146T3 (es) 2010-08-31 2018-03-08 Janssen Biotech, Inc. Diferenciación de células madre embrionarias humanas
AU2011296383B2 (en) * 2010-08-31 2016-03-10 Janssen Biotech, Inc. Differentiation of pluripotent stem cells
WO2013028771A1 (en) 2011-08-23 2013-02-28 Leong Hwei Xian Reversing intestinal inflammation by inhibiting retinoic acid metabolism
AU2012355698B2 (en) 2011-12-22 2018-11-29 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into single hormonal insulin positive cells
US9434920B2 (en) 2012-03-07 2016-09-06 Janssen Biotech, Inc. Defined media for expansion and maintenance of pluripotent stem cells
MX358590B (es) 2012-06-08 2018-08-24 Janssen Biotech Inc Diferenciacion de celulas madre embrionarias humanas en celulas endocrinas pancreaticas.
US10370644B2 (en) 2012-12-31 2019-08-06 Janssen Biotech, Inc. Method for making human pluripotent suspension cultures and cells derived therefrom
US10344264B2 (en) 2012-12-31 2019-07-09 Janssen Biotech, Inc. Culturing of human embryonic stem cells at the air-liquid interface for differentiation into pancreatic endocrine cells
SG10201707811XA (en) 2012-12-31 2017-11-29 Janssen Biotech Inc Differentiation of human embryonic stem cells into pancreatic endocrine cells using hb9 regulators
AU2013370228B2 (en) 2012-12-31 2018-10-18 Janssen Biotech, Inc. Suspension and clustering of human pluripotent cells for differentiation into pancreatic endocrine cells
SG10201810739VA (en) 2014-05-16 2019-01-30 Janssen Biotech Inc Use of small molecules to enhance mafa expression in pancreatic endocrine cells
MA45479A (fr) 2016-04-14 2019-02-20 Janssen Biotech Inc Différenciation de cellules souches pluripotentes en cellules de l'endoderme de l'intestin moyen

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1223654A (zh) * 1996-06-27 1999-07-21 詹森药业有限公司 N－[4－(杂芳基甲基)苯基]－杂芳基胺类化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP869A (en) * 1998-01-05 2000-09-04 Pfizer 2,3-Substituted indole compounds as anti-inflammatory and analgesic agents.
JP2005516941A (ja) * 2001-12-19 2005-06-09 アセロジエニクス・インコーポレイテツド カルコン誘導体及び疾患を治療するためのそれらの使用
US20060205945A1 (en) * 2004-05-14 2006-09-14 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
PL372356A1 (pl) * 2005-01-20 2006-07-24 ADAMED Sp.z o.o. Nowe związki, pochodne kwasu 3-fenylopropionowego
TW200639163A (en) * 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1223654A (zh) * 1996-06-27 1999-07-21 詹森药业有限公司 N－[4－(杂芳基甲基)苯基]－杂芳基胺类化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Vincent C. O. Njar, et al.Retinoic acid metabolism blocking agents (RAMBAs) for treatment of cancer and dermatological diseases.《Bioorganic & Medicinal Chemistry》.2006,第14卷4323-4340. *

Also Published As

Publication number Publication date
AU2007311026A1 (en) 2008-04-24
US8188124B2 (en) 2012-05-29
EP2114895A4 (en) 2011-06-22
JP2010506953A (ja) 2010-03-04
CN101611016A (zh) 2009-12-23
EP2114895A1 (en) 2009-11-11
US20120283204A1 (en) 2012-11-08
US8399495B2 (en) 2013-03-19
US20100292284A1 (en) 2010-11-18
BRPI0718310A2 (pt) 2013-11-19
CA2667053A1 (en) 2008-04-24
WO2008049027A1 (en) 2008-04-24
JP5343267B2 (ja) 2013-11-13
KR20090068286A (ko) 2009-06-25
MX2009004096A (es) 2009-06-16
AU2007311026B2 (en) 2012-05-17
CA2667053C (en) 2015-04-28
KR101419965B1 (ko) 2014-07-16

Similar Documents

Publication Publication Date Title
CN101611016B (zh) 他拉罗唑代谢物
EP1494685B1 (en) Method of treating arrhythmias comprising administration of an a1 adenosine agonist with a beta blocker
EP4337632B1 (en) Resorcinol derivative as a pharmaceutically active compound and method of preparation thereof
US20080114167A1 (en) Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners
US11827605B2 (en) Isoquinoline compounds and their use in treating AhR imbalance
EP2768308B1 (en) Compounds and anti-tumor nqo1 substrates
KR20210052507A (ko) 간 장애 치료
EP2647622B1 (en) Kinesin spindle protein inhibitors and application thereof
EP4520752A1 (en) Carebastine salt and use thereof
US9475836B2 (en) Protopanoxadiol derivative, preparation method thereof and application thereof
EP4183785A1 (en) Novel n-heterocyclic bet bromodomain inhibitor, and preparation method therefor and medical use thereof
CN110770244A (zh) 吡啶并咪唑利福霉素衍生物的抗菌剂
JP2020503366A (ja) グローコカリキシンａ誘導体、その医薬的に許容できる塩または医薬組成物、およびこれらの乾癬治療用医薬の調製における使用
US20020132797A1 (en) DNA-cleaving antitumor agents
CN114907331B (zh) 新一代三唑类氘代化合物及其制备方法和用途
US10975099B2 (en) Thiophene compounds for long-acting injectable compositions and related methods
WO2001070217A1 (en) Dna-cleaving antitumor agents
US20250281425A1 (en) Methods for treating skin disorders with a topical composition of bis-(2-chloroethyl)methylamine
WO2022175907A1 (en) Coumarin compounds and a process for preparation thereof
WO2025097160A1 (en) Methods of enhancing levodopa therapeutic efficacy
KR820001304B1 (ko) 펜아탄올아민의 제조방법
Rump et al. 25. Preliminary Pharmacological Investigations of N-amino-diphenyl-hydantoin, a New Hydantoin Derivative with Prolonged Action

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120125

Termination date: 20151017

EXPY Termination of patent right or utility model